Appointment of Executive Director

RNS Number : 6793T

Advanced Oncotherapy PLC

22 November 2013

 



22 November 2013

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

Appointment of Executive Director

Advanced Oncotherapy (AIM: AVO) is pleased to announce the appointment of Sanjeev Pandya, the Company's acting Chief Operating Officer, as an Executive Director and permanent Chief Operating Officer, with immediate effect.

Sanjeev Pandya, aged 45, trained and practised as an orthopaedic surgeon in the NHS in the UK and in developing countries before working as a strategy consultant with McKinsey & Company.  He then spent two years at Pfizer Global Pharmaceuticals division before joining Lehman Brothers as an investment banker in healthcare M&A.  More recently, he has worked as an independent consultant in Russia and at Bupa in London.  He is a director of Odin Healthcare Limited.   He has a medical degree from Trinity College, Cambridge and an MBA from INSEAD.  

There are no other disclosures to be made regarding Sanjeev Pandya's appointment under paragraph (g) of Schedule 2 of the AIM Rules.

Advanced Oncotherapy's Chairman, Lord Evans of Watford, said, "We are pleased that Sanjeev has accepted our invitation to become our permanent Chief Operating Officer and to join the Board.  Sanjeev has clearly spent some time getting to know the Company, the team and the technology and I am delighted to welcome him to the Board after this process.  Sanjeev's background and commercial experience will add great value to the executive team that he leads as we translate our technology into real world commercial success."

Commenting on his appointment, Sanjeev Pandya said, "I am delighted to be given this opportunity at such an exciting time for the Company. We continue to make strides in all parts of our business from manufacturing to expanding our team of world-renowned advisors and leading experts in their respective fields of business.  I am confident that this technology will revolutionise the fight against cancer."

For further information, please visit www.advancedoncotherapy.comor contact:

Michael Sinclair, Chief Executive	Sandy Jamieson	Jon Levinson/ Lucy Williams	Simon Hudson
Advanced Oncotherapy Plc	Libertas Capital Corporate Finance Ltd	Peterhouse Corporate Finance	Tavistock Communications
	(NOMAD & Joint Broker)	(Joint Broker)	(Financial PR & IR)
[phone]	[phone]	[phone]	[phone]

About Advanced Oncotherapy Plc  

1.   AVO is a provider of radiotherapy services that harnesses the best in modern technology.  As a result, we offer cancer patients affordable access to innovative treatments with proven better health outcomes.

2.   AVO's acquisition of ADAM, a company spin off from CERN (The Large Hadron Collider), focuses on the development of proprietary radiotherapy equipment called LIGHT.  This patented technology offers patients and providers the benefits of proton beam therapy at significantly reduced capital and running costs.

3.   AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT).  This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient.  It is currently available in the UK through BMI, Spire and other hospitals.

-ends-

 

END

 

 

BOAFEAFWFFDSEFF